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Use of combinatorial genetic libraries to humanize
N-linked glycosylation in the yeast Pichia pastoris
Byung-Kwon Choi*, Piotr Bobrowicz*, Robert C. Davidson*, Stephen R. Hamilton*, David H. Kung, Huijuan Li*,
Robert G. Miele*, Juergen H. Nett*, Stefan Wildt*, and Tillman U. Gerngross†
Thayer School of Engineering, Dartmouth College, Hanover, NH 03755
Communicated by Phillips W. Robbins‡, Boston Medical Center, Boston, MA, March 4, 2003 (received for review December 5, 2002)
The secretory pathway of Pichia pastoris was genetically re-engi-
neered to perform sequential glycosylation reactions that mimic early
processing of N-glycans in humans and other higher mammals. After
eliminating nonhuman glycosylation by deleting the initiating -1,6-
mannosyltransferase gene from P. pastoris, several combinatorial
genetic libraries were constructed to localize active -1,2-mannosi-
dase and human-1,2-N-acetylglucosaminyltransferase I (GnTI) in the
secretory pathway. First, >32 N-terminal leader sequences of fungal
type II membrane proteins were cloned to generate a leader library.
Two additional libraries encoding catalytic domains of -1,2-manno-
sidases and GnTI from mammals, insects, amphibians, worms, and
fungi were cloned to generate catalytic domain libraries. In-frame
fusions of the respective leader and catalytic domain libraries resulted
in several hundred chimeric fusions of fungal targeting domains and
catalytic domains. Although the majority of strains transformed with
the mannosidaseleader library displayed only modest in vivo [i.e.,
low levels of mannose (Man)5-(GlcNAc)2] activity, we were able to
isolate several yeast strains that produce almost homogenous N-
glycans of the (Man)5-(GlcNAc)2 type. Transformation of these strains
with a UDP-GlcNAc transporter and screening of a GnTI leader fusion
library allowed for the isolation of strains that produce GlcNAc-
(Man)5-(GlcNAc)2 in high yield. Recombinant expression of a human
reporter protein in these engineered strains led to the formation of
a glycoprotein with GlcNAc-(Man)5-(GlcNAc)2 as the primary N-glycan.
Here we report a yeast able to synthesize hybrid glycans in high yield
and open the door for engineering yeast to perform complex human-
like glycosylation.
The number of protein-based therapeutics entering preclinicaland clinical evaluation has shown robust growth and is expected
to increase in the years to come. Fueled by advances in proteomics
and genomics as well as the ability to engineer and humanize
monoclonal antibodies, protein-based therapeutics constitute500
candidates currently in clinical trials (1). Several therapeutic pro-
teins can be made in a prokaryotic expression system such as
Escherichia coli (e.g., insulin); however, the majority of therapeutic
proteins require additional posttranslational modifications to attain
full biological function. N-glycosylation in particular is essential for
proper folding, pharmacokinetic stability, and efficacy for a large
number of proteins (2). Most therapeutically relevant glycopro-
teins, including antibodies, are therefore expressed in mammalian
cells. However, volumetric productivity, product heterogeneity,
media cost, retroviral contamination, and the time required to
generate stable cell lines are generally viewed as drawbacks of
mammalian cell culture.
Fungal protein-expression systems do not suffer from the same
limitations, and protein titers of 14.8 and 35 gliter have been
reported for secreted heterologous proteins in yeast and the fila-
mentous fungus Trichoderma reesei, respectively (3, 4). However,
glycoproteins derived from fungal expression systems contain non-
human N-glycans of the high mannose (Man) type, which are
immunogenic in humans and thus of limited therapeutic value (5).
Fungi and mammals share initial steps of protein N-glycosylation,
which involves the site-specific transfer of (Glc)3-(Man)9-
(GlcNAc)2 from the luminal side of the endoplasmic reticulum
(ER) to the de novo synthesized protein by an oligosaccharyltrans-
ferase complex. Subsequent trimming by glucosidases I and II and
a specific ER-residing -1,2-mannosidase leads to the formation of
a (Man)8-(GlcNAc)2 structures (isomer Man8B) (Fig. 1), the
N-glycan found on most glycoproteins leaving the ER.
After the export of predominantly (Man)8-(GlcNAc)2 con-
taining glycoproteins to the Golgi, the pathways diverge notably
between mammals and yeast (6). In the human Golgi -1,2-
mannosidases (IA–IC) remove Man to yield the (Man)5-
(GlcNAc)2 structure, which forms the precursor for complex
N-glycans (Fig. 1 A). These mannosidases are typically type II
membrane proteins with an N-terminal cytosolic tail, a trans-
membrane domain, a stem region, and a C-terminal catalytic
domain (Fig. 1B). Localization of these proteins, as with most
enzymes involved in Golgi glycosylation, is mediated by the
cytosolic tail, the transmembrane region, and the stem (7).
In Saccharomyces cerevisiae, N-glycosylation has been studied
extensively and, unlike mammalian N-glycan processing, involves
the addition of numerous Man sugars throughout the entire
Golgi, often leading to hypermannosylated N-glycan structures
with 100 Man residues. This process is initiated in the early
Golgi by an -1,6-mannosyltransferase (Och1p) that prefers
(Man)8-(GlcNAc)2 as a substrate but is able to recognize various
other Man oligomers with the notable exception of the human
(Man)5-(GlcNAc)2 intermediate, which is not a substrate (8).
After addition of this first -1,6-Man by Och1p, additional
-1,6-mannosyltransferases will extend the -1,6 chain, which
then becomes the substrate for medial- and trans-Golgi-residing
-1,2- and -1,3-mannosyltransferases as well as phosphoman-
nosyltransferases that add yet more Man sugars to the growing
N-glycan structure (9). In Pichia pastoris a very similar process
occurs; however, hypermannosylation occurs less frequently and
to a lower extent. In addition -1,3-mannosyltransferase activity
has not been found in this yeast, and N-glycans from P. pastoris
do not have -1,3-Man attached to the outer Man chain (10).
Humanizing the glycosylation machinery of a yeast strain will
require the (i) elimination of some endogenous glycosylation
reactions and (ii) the recreation of the sequential nature of human
glycosylation in the ER and Golgi. Although the first step involves
the generation of gene knockouts (e.g., -1,6- andor -1,3-
mannosyltransferases), the second step requires the proper local-
ization of active mannosidases, glycosyltransferases, and possibly
nucleotide sugar transporters to specific organelles. Moreover the
formation of certain sugar–nucleotide precursor pools such as
CMP-sialic acid may have to be engineered into the yeast host.
Much is known about the localization of endogenous proteins in the
secretory pathway of S. cerevisiae and other yeasts; however, there
is no reliable method to predict whether a Golgi protein from one
Abbreviations: Man, mannose; ER, endoplasmic reticulum; GnTI, -1,2-N-acetylglucosami-
nyltransferase I; MALDI, matrix-assisted laser desorption ionization; K3, Kringle 3 domain
of human plasminogen; TOF, time of flight.
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organism will be properly localized in the Golgi of another organ-
ism. It is also unknown whether artificial in-frame protein fusions
consisting of a yeast localization sequence and a catalytic domain
from a nonyeast source (e.g., glycosyltransferases or mannosidases)
will (i) localize to the desired organelle and (ii) show sufficiently
high activity in the targeted environment. Although proper local-
ization is important, it is not sufficient. Because the activity of the
catalytic domain has to be maintained in the environment in which
it has been localized, additional aspects such as pH optima must be
considered. For example, Chiba et al. (11) found that localizing a
mannosidase with a pH optimum of 5 in the ER of S. cerevisiae
results in only modest intracellular mannosidase activity.
To overcome these major constraints we developed two tools:
a combinatorial genetic library, generating hundreds of fusion
constructs at a time, and a high-throughput screen that allows us
to analyze large numbers of strains in parallel for their ability to
modify N-glycans of recombinant reporter proteins. The com-
binatorial genetic library consists of an array of different fusion-
protein constructs, each of which contains a fungal cellular
targeting sequence fused in frame to a catalytic domain (e.g.,
mannosidase). Each of the 608 generated mannosidase fusion
constructs was tested individually for its ability to catalyze the
trimming of higher Man structures to (Man)5-(GlcNAc)2. Those
strains that were able to generate mostly (Man)5-(GlcNAc)2 on
a secreted reporter protein were subjected first to a second
screen to ensure that trimming occurred in vivo and then
engineered further to generate GlcNAc-(Man)5-(GlcNAc)2 by
screening a similar -1,2-N-acetylglucosaminyltransferase I
(GnTI)leader library. A more comprehensive article describing
the characteristics of 600 leadermannosidase and leader
GnTI fusions is in preparation (B.-K.C., P.B., R.C.D., S.R.H.,
A. Stadheim, H.L., R.G.M., J.H.N., S.W., and T.U.G., unpub-
lished data); however, some of the most important findings are
reported in this article.
Here we report the re-engineering of the secretory pathway in the
methylotrophic yeast P. pastoris. The engineered strain produces
predominantly N-glycans that are intermediates of the human
glycosylation pathway, essentially void of fungal features. Our
results suggest that further implementation of the described com-
binatorial library approach will allow for the engineering of yeast
strains with increasingly human N-glycosylation. This article reports
a genetically engineered yeast capable of producing a glycoprotein
with a human-like hybrid N-glycosylation structure.
Materials and Methods
Strains, Culture Conditions, and Reagents. E. coli strains TOP10 or
DH5 were used for recombinant DNA work. P. pastoris GS115
(his4, Invitrogen) or JC308 (ura3, ade1, arg4, his4, a gift from
James M. Cregg, Keck Graduate Institute, Claremont, CA) were
used for generation of yeast strains. Protein expression was
carried out at room temperature in a 96-well-plate format with
buffered glycerol-complex medium (BMGY) consisting of 1%
yeast extract, 2% peptone, 100 mM potassium phosphate buffer
(pH 6.0), 1.34% yeast nitrogen base, 4  105% biotin, and 1%
glycerol as a growth medium. The induction medium was
buffered methanol-complex medium (BMMY) consisting of
1.5% methanol instead of glycerol in BMGY. Minimal medium
is 1.4% yeast nitrogen base, 2% dextrose, 1.5% agar, and 4 
105% biotin and amino acids supplemented as appropriate.
Restriction and modification enzymes were from New England
BioLabs. Oligonucleotides were obtained from the Dartmouth
College Core facility (Hanover, NH) or Integrated DNA Tech-
nologies (Coralville, IA). The enzymes, peptide N-glycosidase F,
mannosidases, and oligosaccharides were obtained from Glyko
(San Rafael, CA). Metal chelating HisBind resin was from
Novagen. Lysate-clearing plates (96-well) were from Promega.
Protein-binding 96-well plates were from Millipore. Salts and
buffering agents were from Sigma. Matrix-assisted laser desorp-
tion ionization (MALDI) matrices were from Aldrich.
Cloning and Deletion of the P. pastoris OCH1 Gene. The 1,215-bp
ORF of the P. pastoris OCH1 gene encoding a putative -1,6-
mannosyltransferase was amplified from P. pastoris genomic
DNA (strain X-33, Invitrogen) by using the oligonucleotides
5-ATGGCGAAGGCAGATGGCAGT-3 and 5-TTAGTC-
CTTCCAACTTCCTTC-3, which were designed based on the
P. pastoris OCHI sequence (12). Subsequently, 2,685 bp up-
stream and 1,175 bp downstream of the ORF of the OCHI gene
were amplified from a P. pastoris genomic DNA library (gift
from Judah Folkman, Harvard Medical School, Boston) by using
the internal oligonucleotides 5-ATGGCGAAGGCAGATG-
GCAGT-3 and 5-ACTGCCATCTGCCTTCGCCAT-3 in the
OCHI gene with T3 (5-AATTAACCCTCACTAAAGGG-3)
and T7 (5-GTAATACGACTCACTATAGGGC-3) in the
backbone of the library bearing plasmid  ZAP II (Stratagene).
The resulting 5,075-bp fragment was cloned into the pCR2.1-
TOPO vector (Invitrogen) and designated pBK9. To create an
och1 knockout strain containing multiple auxotrophic markers,
100 g of pJN329, a plasmid containing an och1::URA3 mutant
allele (J.F.N., S.W., and T.U.G., unpublished data; see Fig. 2A
for details) was digested with SfiI and used to transform P.
pastoris strain JC308 by electroporation. After incubation on
defined medium lacking uracil for 10 days at room temperature,
1,000 colonies were picked and restreaked. URA clones that
Fig. 1. (A) N-linked glycosylation pathway in humans and P. pastoris. Mns,
-1,2-mannosidase; MnT, mannosyltransferase; Och1p, the initiating 1,6-
mannosyltransferase. (B) Structure of typical type II membrane glycosidase or
glycosyltransferase.
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were unable to grow at 37°C but grew at room temperature were
subjected to colony PCR to test for the correct integration of the
och1::URA3 mutant allele. One clone that exhibited the ex-
pected PCR pattern was designated YJN153.
Reporter Protein-Expression Construct. The Kringle 3 domain of
human plasminogen (K3) was used as a model protein. A DNA
fragment encoding the K3 (gift from Nick Menhart, Illinois
Institute of Technology, Chicago) was amplified by using Pfu
turbo polymerase (Stratagene) and cloned into EcoRI and XbaI
sites of pPICZA (Invitrogen), resulting in a C-terminal 6-His
tag. To improve the N-linked glycosylation efficiency of K3 (13),
Pro-46 was replaced with Ser-46 by using site-directed muta-
genesis. The resulting plasmid was designated pBK64. The
correct sequence of the PCR construct was confirmed by DNA
sequencing.
Integration vectors and fusion constructs were generated
based on the roll-in plasmids described by Lin Cereghino and
coworkers (14); see details in Supporting Methods, which is
published as supporting information on the PNAS web site,
www.pnas.org.
Generation of Yeast Strains. To create P. pastoris strains expressing
the K3, plasmid pBK64 was transformed into strains GS115 and
YJN153, and colonies were selected on YPD medium containing
100 gml zeocin to create strains BK64 and BK64-1, respec-
tively. Plasmid pPB103 was linearized with EcoNI and trans-
formed into strain BK64-1, and colonies were selected on
defined medium lacking adenine. One strain containing the
Kluyveromyces lactis MNN2-2 gene was designated PBP1. Plas-
mids pBB27 and pBC4 were linearized with SalI and trans-
formed into strain PBP1, and colonies were selected on defined
medium lacking histidine. Strains that were confirmed to contain
the Caenorhabditis elegans -1,2-mannosidase IB BB27 and BC4
fusion constructs were designated YJN188 and YJN168, respec-
tively. Plasmid pNA15 was linearized with AatII and transformed
into strain YJN168, and colonies were selected on minimal
medium without amino acids. One strain that was confirmed to
contain the human GnTI gene fusion was designated YJN201.
Western Blotting. Proteins were separated by 4–20% gradient
SDSPAGE according to Laemmli (15) and then electroblotted
onto nitrocellulose membrane (Schleicher & Schuell) as de-
scribed (16). P. pastoris Och1p was detected by using an antibody
raised against the peptide CQQLSSPKIDYDPLTL (Sigma–
Genosys) with an ECL kit (Amersham Pharmacia).
Protein Purification. K3 was purified from the medium by Ni-
affinity chromatography by using a 96-well format on a Beckman
BioMek 2000 laboratory robot. The robotic purification is an
adaptation of the protocol provided by Novagen for their
HisBind resin.
Release of N-Linked Glycans. The glycans were released and sep-
arated from the glycoproteins by a modification of a previously
reported method (17). After the proteins were reduced and
carboxymethylated and the membranes were blocked, the wells
were washed three time with water. The protein was deglyco-
sylated by the addition of 30 l of 10 mM NH4HCO3 (pH 8.3)
containing 1 milliunit of N-glycanase (Glyko). After 16 h at 37°C,
the solution containing the glycans was removed by centrifuga-
tion and evaporated to dryness.
MALDITime-of-Flight (TOF) Mass Spectrometry. Molecular weights
of the glycans were determined by using a Voyager DE PRO linear
MALDITOF (Applied Biosciences) mass spectrometer with de-
layed extraction. The dried glycans from each well were dissolved
in 15 l of water, and 0.5 l was spotted on stainless-steel sample
plates and mixed with 0.5 l of S-DHB matrix (9 mg/ml of
dihydroxybenzoic acid1 mg/ml of 5-methoxysalicylic acid in 1:1
water/acetonitrile0.1% trifluoroacetic acid) and allowed to dry.
Ions were generated by irradiation with a pulsed nitrogen laser (337
nm) with a 4-ns pulse time. The instrument was operated in the
delayed extraction mode with a 125-ns delay and an accelerating
voltage of 20 kV. The grid voltage was 93.00%, guide wire voltage
was 0.1%, the internal pressure was 5  107 torr (1 torr  133
Pa), and the low mass gate was 875 Da. Spectra were generated
from the sum of 100–200 laser pulses and acquired with a 500-MHz
digitizer. (Man)5-(GlcNAc)2 oligosaccharide was used as an exter-
nal molecular weight standard. All spectra were generated with the
instrument in the positive-ion mode.
Mannosidase Assays. Fluorescence-labeled (Man)8-(GlcNAc)2
(0.5g) was added to 20l of supernatant and incubated for 30 h
at room temperature. After incubation the sample was analyzed
by HPLC with an Econosil NH2 4.6  250-mm, 5-m bead,
amino-bound silica column (Alltech, Avondale, PA). The flow
rate was 1.0 mlmin for 40 min, and the column was maintained
at 30°C. After eluting isocratically (68% A:32% B) for 3 min, a
linear solvent gradient (68% A:32% B to 40% A:60% B) was
used over 27 min to elute the glycans (18). Solvent A was
acetonitrile, and solvent B was an aqueous solution of ammo-
nium formate, 50 mM (pH 4.5). The column was equilibrated
with solvent (68% A:32% B) for 20 min between runs.
Results
Generation of an -1,6-Mannosyltransferase Deletion Mutant in P.
pastoris. In S. cerevisiae the OCH1 gene product (Och1p) is an
-1,6-mannosyltransferase that initiates the outer-chain elonga-
tion of N-linked glycans in the early Golgi. An och1 null mutant
strain in S. cerevisiae shows no -1,6-Man linkage to the core
glycan structure and consequently lacks hyperglycosylation (19).
To generate a deletion of the OCH1 homolog in P. pastoris an
och1::URA3 mutant allele was constructed and transformed into
a ura3 strain of P. pastoris (JC308). Several och1 mutant strains
were identified and confirmed by PCR and Western blotting
(Fig. 2B). The P. pastoris och1 mutant strain exhibited temper-
ature sensitivity and increased flocculation similar to that ob-
served in S. cerevisiae (data not shown).
Glycan structures of heterologous proteins expressed in P.
pastoris are heterogeneous, mostly consisting of (Man)10–16-
(GlcNAc)2 mannans with varying degrees of charged glycans (10,
20). To monitor the effect of different engineering steps on the
glycosylation of P. pastoris, a secreted form of K3 was used as a
reporter protein. Hyperglycosylation observed by SDSPAGE
Fig. 2. Knockout of OCHI in P. pastoris. (A) The OCHI knockout plasmid
pJN329 contains the P. pastoris URA3 gene flanked by LacZ repeats and 2,878
bp upstream (5) and 1,011 bp downstream (3) of the OCHI gene of P. pastoris.
(B) Immunoblot of Och1p in Pichia wild type (JC308, lane 1) and och1 mutant
(BK64-1, lane 2). The same amount of cell-free extract (50 g per lane) was
used, and Och1p was detected by using an Och1p peptide antibody followed
by ECL. (C) The reporter protein K3 was expressed in Pichia wild type BK64
(lane 1) and an och1 mutant, P. pastoris BK64-1 (lane 2). K3 was purified by
Ni-affinity chromatography, separated by SDSPAGE (4–20% gradient) under
reducing conditions, and visualized by silver staining. The same amount of K3
(200 ng per lane) was loaded.
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analysis when K3 was expressed in a wild-type P. pastoris strain
was eliminated in the och1 mutant strain (Fig. 2C). N-glycans
released from secreted K3 were analyzed directly by MALDI
TOF mass spectrometry. N-glycans of K3 expressed in a P.
pastoris wild-type strain were found to have a molecular mass
consistent with (Man)10–16-(GlcNAc)2, confirming previous
findings in this yeast (Fig. 3A). By comparison, the N-glycans of
K3 in an och1 mutant strain revealed predominantly (Man)8–12-
(GlcNAc)2, representing a noticeable shift to smaller glycans
(Fig. 3B) and a complete elimination of the smearing observed
in the SDSPAGE analysis (Fig. 2C). To rule out the possibility
of protein-specific interactions a second reporter protein, full-
length human IFN-, was used and revealed identical results
(data not shown).
Construction of ERGolgi leader, -1,2-Mannosidase, and GnTI
Libraries. To sequentially localize different mannosidases and Gn-
TIs along the early secretory pathway of P. pastoris three separate
gene libraries were designed. The first library (the leader library)
contained DNA fragments encoding N-terminal peptides of known
type II membrane proteins that either localize in the ER or Golgi
of S. cerevisiae and P. pastoris. They include Gls1, Mns1, Sec12,
Mnn9, Van1, Anp1, Hoc1, and Mnn10, Mnn11 from S. cerevisiae
and Och1 and Sec12 from P. pastoris. The generation of the
respective DNA constructs is exemplified by the construction of
Mns1, Mnn9, and Mnn10 leaders in Materials and Methods. A
second library contained catalytic domains of -1,2-mannosidases
from Homo sapiens, Mus musculus, Aspergillus nidulans, C. elegans,
Drosophila melanogaster, and Penicillium citrinium. The generation
of the respective DNA constructs is exemplified by the construction
of mannosidase IB from C. elegans in Materials and Methods.
Finally, a third library contained catalytic domains of GnTI genes
from H. sapiens, C. elegans, Xenopus laevis, and D. melanogaster. All
libraries were designed in a way that any combination of a leader
construct and a catalytic domain created a gene encoding a
chimeric fusion protein.
Each leader fragment was represented in three lengths. The
short form encoded the N-terminal cytoplasmic tail and the
transmembrane domain. The long form encoded additional
residues containing the complete stem region up to the respec-
tive catalytic domain, which was determined by sequence ho-
mology to known catalytically active fragments of such enzymes.
The medium form was an intermediate version containing
approximately half of the stem region in addition to the sequence
encoded in the short form. Catalytic domains were selected to
cover a wide range of pH optima as determined from literature
data (e.g., P. citrinium and M. musculus) and temperature optima
by selecting domains from organisms that exist at different
temperatures (e.g., C. elegans and H. sapiens). Each catalytic
domain was represented in several lengths and generally lacked
the native N-terminal cytosolic and transmembrane domain.
Some of the catalytic domains were selected solely on the basis
Fig. 3. Positive-ion MALDITOF mass spectra of N-linked glycans released
from K3. K3 was produced in P. pastoris strains BK64, BK64-1, YJN168, YJN188,
and YJN201 and purified from culture supernatants by Ni-affinity chromatog-
raphy. The glycans were released from K3 by peptide N-glycosidase F treat-
ment. The released N-linked glycans were analyzed by MALDITOF mass
spectrometry, typically appearing as the sodium or potassium adducts. (A)
BK61, wild-type strain of P. pastoris expressing K3. (B) BK64-1, och1 deletion
expressing K3. (C) YJN168, och1 deletion expressing K3, K. lactis UDP-GlcNAc
transporter, and C. elegans -1,2-mannosidase IB fused to MNS1. (D) YJN188,
och1 deletion expressing K3, K. lactis UDP-GlcNAc transporter, and C. elegans
-1,2-mannosidase IB fused to MNN10. (E) YJN201, och1 deletion expressing
K3, K. lactis UDP-GlcNAc transporter, C. elegans-1,2-mannosidase IB fused to
MNS1, and human GnTI fused to MNN9. (F) YJN201 after -N-acetylhex-
osaminidase treatment. M, Man.
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of sequence homology to other known -1,2-mannosidases (e.g.
C. elegans) or GnTIs and had not been characterized previously.
After screening the fusion libraries chimeric constructs were
identified that displayed a high degree of Man-trimming activity
and UDP-GlcNAc transfer activity on the reporter protein K3.
A detailed analysis of the characteristics of the fusion libraries
will be published elsewhere (B.-K.C., P.B., R.C.D., S.R.H.,
A. Stadheim, H.L., R.G.M., J.H.N., S.W., and T.U.G., unpub-
lished data).
Expression of -1,2-Mannosidase Fusion Constructs in a P. pastoris
och1 Mutant Strain. After screening a library of 608 leader-1,2-
mannosidase fusions targeted to the ER and early Golgi, several
clones were identified that produced N-glycans consistent with
a mass of (Man)5-(GlcNAc)2. Specifically, a putative C. elegans
homolog of known -1,2-mannosidases showed a high degree of
trimming to (Man)5-(GlcNAc)2 when fused to both the S.
cerevisiae MNS1 and MNN10 leader-encoding fragments. Al-
though these constructs and several others resulted in glycans,
which were 70–80% or more (Man)5-(GlcNAc)2 (Fig. 3 C and
D), 56% of the fusions resulted in 10% (Man)5-(GlcNAc)2
(Table 1). These data clearly emphasize the importance of
choosing the proper combination of (i) a localization sequence
and (ii) an -1,2-mannosidase catalytic domain of the proper
length. Fungal -1,2-mannosidases with acidic pH optima (e.g.,
P. citrinium and A. nidulans), when expressed as fusions with the
leader library, generally resulted in low (Man)5-(GlcNAc)2 yields
(data not shown) consistent with previous findings (11, 21).
Because previous researchers have found that trimming to
(Man)5-(GlcNAc)2 was often accompanied by leakage of man-
nosidase into the medium (22), we further investigated whether
Man trimming occurred in vivo, in the Golgi, or ex vivo after
secretion of the protein into the medium. To determine the
extent of mannosidase activity in the medium, 2-aminobenz-
amide-labeled (Man)8-(GlcNAc)2 was used to assay the culture
supernatant. Many of the efficient (Man)5-(GlcNAc)2-producing
constructs displayed a high degree of mannosidase activity in the
supernatant, suggesting that at least some of the observed
(Man)5-(GlcNAc)2 structures were produced ex vivo. However,
by applying a double screen we were able to identify specific
chimeric fusions that were entirely retained intracellularly while
at the same time displaying high in vivo -1,2-mannosidase
activity (Fig. 4C).
Expression of GnTI Fusion Constructs in a P. pastoris och1 Mutant
Strain Containing an Active -1,2-Mannosidase. Further humaniza-
tion of (Man)5-(GlcNAc)2 glycan structures involves the subse-
quent in vivo conversion of (Man)5-(GlcNAc)2 to GlcNAc-
(Man)5-(GlcNAc)2. This step requires UDP-GlcNAc as a
substrate and involves the transfer of GlcNAc to (Man)5-
(GlcNAc)2 by GnTI (Fig. 1). To ensure sufficient levels of
UDP-GlcNAc in the Golgi we cloned the UDP-GlcNAc trans-
porter from K. lactis into an och1 mutant strain, which also
displays high in vivo mannosidase activity.
A leaderGnTI fusion library containing 67 constructs was
screened. Among several active fusion constructs, one consisting
of human GnTI and a leader sequence from S. cerevisiae MNN9
was particularly active, and the corresponding strains yielded
K3-containing glycans with a mass consistent with GlcNAc-
(Man)5-(GlcNAc)2 almost exclusively (Fig. 3E). Moreover, these
glycans were converted completely to (Man)5-(GlcNAc)2 by in
vitro N-acetylhexosaminidase digestion, further indicating that
this strain secretes protein almost uniformly modified with
glycans of the structure GlcNAc-(Man)5-(GlcNAc)2, a well
described human glycosylation intermediate (Fig. 3F). Impor-
tantly, GnTI activity was assayed in the culture medium of this
strain and found to be absent (data not shown). Finally, to
determine whether the UDP-GlcNAc transporter was required
to provide sufficient amounts of substrate for GnTI, a strain
producing (Man)5-(GlcNAc)2 was transformed with the same
GnTI construct in the absence of the transporter. Although some
GlcNAc-(Man)5-(GlcNAc)2 was observed from the purified K3,
a large percentage of glycans consistent with (Man)5-(GlcNAc)2
remained, indicating that GlcNAc transfer was less efficient than
in the strain containing the transporter (data not shown). This
result confirms the purported necessity of a UDP-GlcNAc
transporter for efficient GlcNAc transfer originally found in K.
lactis (23).
Discussion
P. pastoris is one of several yeasts capable of high-level production
of heterologous glycoproteins (24). As with any other fungal
Fig. 4. Extracellular activity of C. elegans -1,2-mannosidase IB. 2-Amino-
benzamide-labeled (Man)8-(GlcNAc)2 was incubated with culture superna-
tants at 25°C for 30 h and analyzed by HPLC. (A) (Man)8-(GlcNAc)2 standard in
BMMY medium (no cells). (B) Supernatant from YJN188. (C) Supernatant from
YJN168. M, Man.
Table 1. Relative amount of (Man)5 on secreted K3
Amount of (Man)5 on secreted K3,
% of total glycans Number of constructs (%)
ND* 19 (3.1)
0–10 341 (56.1)
10–20 50 (8.2)
20–40 75 (12.3)
40–60 72 (11.8)
60 51 (8.4)†
Total 608 (100)
Six hundred and eight different strains of P. pastoris (och1) were generated
by transforming them with a single construct of a combinatorial genetic
library that was generated by fusing 19 -1,2-mannosidase catalytic domains
to 32 fungal ER and cis-Golgi leaders.
*Several fusion constructs were not tested because the corresponding plas-
mids could not be propagated in E. coli before transformation into P.
pastoris.
†Clones with the highest degree of (Man)5 trimming (3051) were analyzed
further for mannosidase activity in the supernatant of the medium. The
majority (2830) displayed detectable mannosidase activity in the superna-
tant (e.g. Fig. 4B). Only two constructs displayed high (Man)5 levels while
lacking mannosidase activity in the medium (e.g. Fig. 4C).
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protein-expression systems, the heterologous glycoprotein is glyco-
sylated in a fungal-like fashion generally involving the addition of
-1,6- and -1,2-linked Man and mannosylphosphate to the
(Man)8-(GlcNAc)2 core (Fig. 1; ref. 25). This yeast-type glycosyl-
ation pattern is recognized by the human immune system, which
renders the underlying protein unfit for therapeutic use. In view of
the current shortage of efficient glycoprotein-expression systems we
have focused our efforts on engineering commercially relevant
yeast and filamentous fungi to produce N-glycans with human-like
glycosylation structures. In this study we report the construction of
a strain that produces high levels of a reporter protein modified with
a human glycosylation intermediate in the P. pastoris system.
The first step in attaining complex human-type glycans in a
fungal system is to eliminate yeast-type glycosylation. To accom-
plish this, the P. pastoris OCH1 gene was deleted in a strain
secreting the reporter protein K3. Yeast-type hyperglycosylation
was abrogated in this strain as observed by silver staining of
secreted K3 (Fig. 2C), and when released N-glycans were
analyzed by MALDITOF, a general trend toward smaller
structures was observed (Fig. 3B).
Once an appropriate core high-Man glycan is obtained, the
next immediate step in the conversion to human-type N-glycans
involves the functional expression and localization of an -1,2-
mannosidase. This enzyme will trim the (Man)8-(GlcNAc)2 core
structure to (Man)5-(GlcNAc)2 and thereby generate the struc-
ture that is capable of receiving the GlcNAc that initiates the
formation of hybrid N-glycans. A very similar approach was
taken in a triple mutant och1 mnn1 mnn4 strain of S. cerevisiae
(11). ER localization of a fungal -1,2-mannosidase (from
Aspergillus saitoi) was accomplished by adding the tetrapeptide
HDEL as an ER retrieval tag to the C terminus of the gene. By
using the S. cerevisiae GAPDH promoter and a multicopy
number plasmid, mannosidase activity was detectable in cell-free
extracts; however, only 27% of the N-glycans of an endogenous
marker protein (carboxypeptidase Y) were trimmed from
(Man)8-(GlcNAc)2 to (Man)5-(GlcNAc)2 in vivo. Although not
entirely successful, the pioneering work of Chiba et al. (11)
demonstrates that N-glycans from S. cerevisiae can be modified
substantially by engineering glycosylation pathways. Here the
localization of catalytic domains to the secretory pathway of the
related yeast P. pastoris using yeast type II membrane protein
leader domains is demonstrated. The benefit of a large library of
leader domains along with an equally diverse library of catalytic
domains allowed for the selection of the most active fusion
constructs from a pool of 600 candidates, many of which were
marginally active or not at all. Despite the lack of success of many
constructs, a few particularly active enzyme fusions were able to
trim the core (Man)8–12-(GlcNAc)2 glycans observed in the och1
mutant strain to (Man)5-(GlcNAc)2. Two of these constructs
described here, which are fusions of a putative C. elegans
-1,2-mannosidase with different yeast type II leader domains,
are able to do so at high efficiency (75%).
The correct localization of enzymes involved in glycosylation
is critical to allow for the sequential glycan modifications as
glycoproteins proceed through the secretory pathway. However,
one additional concern has come from another previous attempt
to engineer glycans in P. pastoris, which was undertaken with an
-1,2-mannosidase from T. reesei (22). In this study immunoflu-
orescent microscopy was used to demonstrate that a mannosi-
dase-myc-HDEL fusion localized primarily in the ER of P.
pastoris; however, leakage into the medium was also observed by
Western blotting. Because the secreted glycoprotein of interest
will be in the supernatant for many hours, the cosecretion of
mannosidases into the medium is of concern because it can be
misinterpreted as in vivo activity. It is important to generate
(Man)5-(GlcNAc)2 structures in vivo, and early in the secretory
pathway, if subsequent conversion to complex glycans is to be
achieved. Although it is well established that the ERD2-based
retrieval system is leaky and retention of the HDEL-tagged
mannosidase in the secretory pathway cannot be ensured (26),
the same concern is emphasized further by the striking differ-
ence demonstrated here between the two different C. elegans
-1,2-mannosidase IB fusion constructs. Thus, the use of a series
of different fusion constructs with many differentially localized
type II domains has allowed us to screen for chimera with activity
that is completely in vivo.
After efficient trimming of the core glycan to (Man)5-
(GlcNAc)2 the next step in the conversion of high Man-type
glycans to hybrid- and complex-type glycans involves the expres-
sion and localization of the enzyme GnTI. Here again a library
of GnTI catalytic domains was used and allowed for the screen-
ing for and selection of several particularly active GnTI fusion
constructs for further study. One particularly active fusion using
the human GnTI catalytic domain shown here converts the
(Man)5-(GlcNAc)2 substrate to the desired GlcNAc-(Man)5-
(GlcNAc)2 product almost quantitatively, an activity that was
shown to be completely in vivo. Furthermore, the demonstrated
activity of GnTI on the (Man)5-(GlcNAc)2 substrate is the best
evidence that the -1,2-mannosidase activity is indeed occurring
in the secretory pathway. This is a demonstration of a high-level
hybrid N-glycan modification of a secreted protein in yeast and
represents a significant step toward the ability to express fully
human glycoproteins in yeast. Although the generated structures
are expected to be nonimmunogenic in humans, additional Man
removal (i.e., the removal of 1,6- and 1,3-Man from the tri-
mannose core) and further addition of -1,2-GlcNAc will be
required to generate complex N-glycans of therapeutic utility
(e.g., for the production of monoclonal antibodies).
We thank Beata Bobrowicz, Teresa Mitchell, Sebastian Rausch, Andy
Stadheim, Amelia Walling, and Harry Wischnewski for technical assis-
tance. We gratefully acknowledge the gift of strains and reagents from
Judah Folkman, James Cregg, Nick Menhart, Robert Barsteadt, Carlos
Hirschberg, and Takashi Yoshida. We also thank Phil Robbins and
Roger Bretthauer for their encouragement and continued support.
1. Walsh, G. (2000) Nat. Biotechnol. 18, 831–833.
2. Helenius, A. & Aebi, M. (2001) Science 291, 2364–2369.
3. Werten, M. W. T., van den Bosch, T. J., Wind, R. D., Mooibroek, H. & de Wolf, F. A. (1999)
Yeast 15, 1087–1096.
4. Durand, H. & Clanet, M. (1988) Enzyme Microb. Technol. 10, 341–346.
5. Ballou, C. E. (1990) Methods Enzymol. 185, 440–470.
6. Hubbard, S. C. & Ivatt, R. J. (1981) Annu. Rev. Biochem. 50, 555–583.
7. Gleeson, P. A. (1998) Histochem. Cell Biol. 109, 517–532.
8. Nakayama, K., Nakanishi-Shindo, Y., Tanaka, A., Haga-Toda, Y. & Jigami, Y. (1997) FEBS
Lett. 412, 547–550.
9. Dean, N. (1999) Biochim. Biophys. Acta 1426, 309–322.
10. Bretthauer, R. K. & Castellino, F. J. (1999) Biotechnol. Appl. Biochem. 30, 193–200.
11. Chiba, Y., Suzuki, M., Yoshida, S., Yoshida, A., Ikenaga, H., Takeuchi, M., Jigami, Y. &
Ichishima, E. (1998) J. Biol. Chem. 273, 26298–26304.
12. Koji, M., Narutoshi, S. & Tomoyasu, R. (1996) Jpn. Patent JP 8336387.
13. Hayes, M. L., Bretthauer, R. K. & Castellino, F. J. (1975) Arch. Biochem. Biophys. 171,
651–655.
14. Lin Cereghino, G. P., Lin Cereghino, J., Sunga, A. J., Johnson, M. A., Lim, M., Gleeson,
M. A. & Cregg, J. M. (2001) Gene 263, 159–169.
15. Laemmli, U. K. (1970) Nature 227, 680–685.
16. Towbin, H. & Gordon, J. (1984) J. Immunol. Methods 72, 313–340.
17. Papac, D. I., Briggs, J. B., Chin, E. T. & Jones, A. J. S. (1998) Glycobiology 8, 445–454.
18. Turco, S. J. (1981) Anal. Biochem. 118, 278–283.
19. Nakanishi-Shindo, Y., Nakayama, K. I., Tanaka, A., Toda, Y. & Jigami, Y. (1993) J. Biol.
Chem. 268, 26338–26345.
20. Trimble, R. B., Atkinson, P. H., Tschopp, J. F., Townsend, R. R. & Maley, F. (1991) J. Biol.
Chem. 266, 22807–22817.
21. Martinet, W., Maras, M., Saelens, X., Jou, W. M. & Contreras, R. (1998) Biotechnol. Lett.
20, 1171–1177.
22. Callewaert, N., Laroy, W., Cadirgi, H., Geysens, S., Saelens, X., Jou, W. M. & Contreras,
R. (2001) FEBS Lett. 503, 173–178.
23. Guillen, E., Abeijon, C. & Hirschiberg, C. B. (1998) Proc. Natl. Acad. Sci. USA 95,
7888–7892.
24. Lin Cereghino, J. & Cregg, J. M. (2000) FEMS Microbiol. Rev. 24, 45–66.
25. Miele, R. G., Castellino, F. J. & Bretthauer, R. K. (1998) Biotechnol. Appl. Biochem. 26,
79–83.
26. Pelham, H. R. B. (2000) Methods Enzymol. 327, 279–283.
Choi et al. PNAS  April 29, 2003  vol. 100  no. 9  5027
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
